{
  "id": 19283,
  "label": "therapy related acute myeloid leukemia and myelodysplastic syndrome",
  "model": {
    "label": "Mondo Disease Ontology (MONDO)",
    "source": 0
  },
  "type_id": 0,
  "reference_id": "MONDO:0019457",
  "properties": {
    "xrefs": [
      "GARD:0012762",
      "MEDGEN:220954",
      "NCIT:C25765",
      "Orphanet:86846",
      "SCTID:721306009",
      "UMLS:C1292776",
      "icd11.foundation:1581599493"
    ],
    "synonyms": [
      "Secondary AGL",
      "Secondary Acute granulocytic Leukaemia",
      "Secondary Acute granulocytic Leukemia",
      "Secondary Acute myeloblastic Leukaemia",
      "Secondary Acute myeloblastic Leukemia",
      "Secondary Acute myelocytic Leukaemia",
      "Secondary Acute myelocytic Leukemia",
      "Secondary Acute myelogenous Leukaemia",
      "Secondary Acute myelogenous Leukemia",
      "Secondary Acute myeloid Leukaemia (AML)",
      "Secondary Acute myeloid Leukemia (AML)",
      "secondary AML",
      "secondary acute myeloid leukaemia",
      "secondary acute myeloid leukemia",
      "therapy-related AML and myelodysplastic syndrome"
    ],
    "categories": [
      {
        "ref": "MONDO:0002081",
        "name": "musculoskeletal system disorder"
      },
      {
        "ref": "MONDO:0003900",
        "name": "connective tissue disorder"
      },
      {
        "ref": "MONDO:0005046",
        "name": "immune system disorder"
      },
      {
        "ref": "MONDO:0005570",
        "name": "hematologic disorder"
      }
    ],
    "definition": "An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001)"
  },
  "isLeaf": false,
  "isRoot": false,
  "child_count": 3,
  "parents": [
    {
      "id": 18806,
      "label": "acute myeloid leukemia",
      "isLeaf": false,
      "isRoot": false,
      "parents": [
        6429,
        11789
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "DOID:9119",
          "EFO:0000222",
          "GARD:0012757",
          "ICD10CM:C92.0",
          "ICD9:205.0",
          "ICD9:205.00",
          "ICDO:9861/3",
          "MEDGEN:9730",
          "MESH:D015470",
          "MedDRA:10000880",
          "NCIT:C3171",
          "NORD:1905",
          "OMIM:601626",
          "ONCOTREE:AML",
          "Orphanet:519",
          "SCTID:91861009",
          "UMLS:C0023467"
        ],
        "synonyms": [
          "AML",
          "AML - acute myeloid leukaemia",
          "AML - acute myeloid leukemia",
          "ANLL",
          "acute Nonlymphocytic leukaemia",
          "acute Nonlymphocytic leukemia",
          "acute granulocytic leukaemia",
          "acute granulocytic leukemia",
          "acute myeloblastic leukemia",
          "acute myelocytic leukaemia",
          "acute myelocytic leukemia",
          "acute myelogenous leukemia",
          "acute myelogenous leukemias",
          "acute myeloid leukaemia (AML)",
          "acute myeloid leukemia",
          "acute myeloid leukemia (AML)",
          "acute myeloid leukemia, somatic",
          "acute nonlymphocytic leukaemia",
          "acute nonlymphocytic leukemia",
          "hematopoeitic - acute Myleogenous leukaemia (AML)",
          "hematopoeitic - acute Myleogenous leukemia (AML)",
          "leukemia, acute myeloid, autosomal dominant, somatic mutation",
          "leukemia, acute myeloid, reduced survival in, somatic",
          "leukemia, acute myeloid, somatic",
          "leukemia, acute myeloid, susceptibility to, autosomal dominant, somatic mutation",
          "leukemia, myelocytic, acute",
          "myeloid leukemia, acute",
          "myeloid leukemia, acute, M4/M4Eo subtype, somatic",
          "acute non lymphoblastic leukaemia",
          "acute non lymphoblastic leukemia",
          "leukemia, acute myelogenous",
          "leukemia, acute myeloid",
          "leukemia, acute myeloid, susceptibility to"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. AML manifests by fever, pallor, anemia, hemorrhages and recurrent infections."
      },
      "child_count": 156,
      "reference_id": "MONDO:0018874"
    }
  ],
  "children": [
    {
      "id": 16090,
      "label": "acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent",
      "isLeaf": true,
      "isRoot": false,
      "parents": [
        19283
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "GARD:0019835",
          "MEDGEN:233970",
          "NCIT:C27913",
          "Orphanet:102379",
          "UMLS:C1332234",
          "icd11.foundation:1401970160"
        ],
        "synonyms": [
          "AML and myelodysplastic syndromes related to alkylating agent"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain)."
      },
      "child_count": 0,
      "reference_id": "MONDO:0015164"
    },
    {
      "id": 16091,
      "label": "acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor",
      "isLeaf": true,
      "isRoot": false,
      "parents": [
        19283
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "GARD:0019836",
          "MEDGEN:1639654",
          "Orphanet:102381",
          "UMLS:C4707659",
          "icd11.foundation:88207494"
        ],
        "synonyms": [
          "AML and myelodysplastic syndromes related to topoisomerase type 2 inhibitor"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposid, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement."
      },
      "child_count": 0,
      "reference_id": "MONDO:0015165"
    },
    {
      "id": 16402,
      "label": "acute myeloid leukemia and myelodysplastic syndromes related to radiation",
      "isLeaf": true,
      "isRoot": false,
      "parents": [
        19283
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "GARD:0020057",
          "MEDGEN:1637827",
          "Orphanet:164726",
          "UMLS:C4707660"
        ],
        "synonyms": [
          "AML and myelodysplastic syndromes related to radiation"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "Acute myeloid leukemia and myelodysplastic syndromes related to radiation represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with radiation. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. Patients frequently present with multilineage dysplasia and cytopenias 5-10 years after exposure."
      },
      "child_count": 0,
      "reference_id": "MONDO:0015608"
    }
  ],
  "roots": [
    {
      "id": 18806,
      "label": "acute myeloid leukemia"
    }
  ]
}